严重主动脉瓣狭窄患者使用当代心包生物瓣膜置换的早中期结果
本研究比较Trifecta(TR)与Carpentier-Edwards Magna Ease(ME)两种心包生物瓣膜在严重主动脉瓣狭窄患者中的早中期临床结局。共纳入TR组331例、ME组360例,采用逆概率加权分析。结果显示两组在复合终点、全因死亡率、结构性瓣膜退化等方面均无显著差异,早期血流动力学优势未转化为中期临床获益。
要点
- TR瓣与ME瓣在复合终点(心源性死亡、再干预、首次心力衰竭)上无显著差异
- 两组全因死亡率无差异,5年生存率ME组91.9%、TR组93.4%
- 结构性瓣膜退化发生率及心力衰竭住院率两组无差异
核心结论
- TR瓣的早期血流动力学优势未转化为与ME瓣相比的中期临床结局差异,需长期随访验证。
研究设计与样本
- 回顾性队列研究,纳入严重主动脉瓣狭窄行主动脉瓣置换术患者,TR组331例、ME组360例,排除合并冠状动脉旁路移植术以外的同期手术,采用逆概率加权分析。
主要发现
- 加权后两组复合终点无显著差异(P > .05);全因死亡风险比0.82(95%CI 0.42-1.59,P = .56);5年生存率ME组91.9%、TR组93.4%;心源性死亡、再干预、首次心力衰竭及结构性瓣膜退化均无差异;每100例患者心力衰竭住院率无差异(P = .19)。
临床怎么用
- 在严重主动脉瓣狭窄患者选择TR或ME瓣膜时,中期临床结局相似,瓣膜选择可综合考虑其他因素。
局限性
- 为回顾性研究,需长期随访以评估远期临床结局差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinical studies have demonstrated improved gradients after aortic valve replacement with the Trifecta (TR) valve (Abbott Cardiovascular, St Paul, MN) as compared with the Carpentier-Edwards Magna Ease (ME) valve (Edwards Lifesciences, Irvine, CA). Clinical benefits of this strategy have not been demonstrated. METHODS: Patients undergoing aortic valve replacement for severe aortic stenosis with either valve were included. Patients were excluded if they underwent concomitant procedures other than coronary artery bypass grafting. Inverse proportion treatment weighting was used in the analysis. The primary outcome was a composite of cardiac mortality, need for reintervention, and freedom from first congestive heart failure (CHF). Secondary outcomes were all-cause mortality, the composite components, and cumulative CHF admission. Follow-up echocardiograms were assessed in a cohort of patients to assess structural valve degeneration. RESULTS: There were 331 patients in the TR group and 360 patients in the ME group. The TR group had more women (48% vs 32%, P < .001) with smaller roots (left ventricular outflow tract diameter: TR, 2.11 cm; ME, 2.17 cm; P < .001). After weighting there was no significant difference in the composite measure between groups (P > .05). There was no difference in all-cause mortality (hazard ratio, 0.82; 95% confidence interval, 0.42-1.59; P = .56), and 5-year survival was 91.9% in the ME group and 93.4% in the TR group. There was no difference in cardiac death, reintervention, or first onset of CHF or incidence of structural valve degeneration between groups. There was no difference in the rate of admissions for CHF per 100 patients between the 2 valve types (P = .19). CONCLUSIONS: Early hemodynamic benefits have not translated into differences in medium-term clinical outcomes between these 2 valves. Long-term follow-up is necessary.
引用
- Rubens FD, Ngu J, Malvea A, et al. Early Midterm Results After Valve Replacement With Contemporary Pericardial Prostheses for Severe Aortic Stenosis. Ann Thorac Surg. 2020. PMID: 33080239. doi:10.1016/j.athoracsur.2020.08.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。